Assessing the psychedelic "after-glow" in ayahuasca users: Post-acute neurometabolic and functional connectivity changes are associated with enhanced mindfulness capacities
Open accessThe DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index; none of the 77 sources its claims cite is checked for support yet.
Abstract
Background: Ayahuasca is a plant tea containing the psychedelic 5-HT2A agonist N,N-dimethyltryptamine and harmala monoamine-oxidase inhibitors. Acute administration leads to neurophysiological modifications in brain regions of the default mode network, purportedly through a glutamatergic mechanism. Post-acutely, ayahuasca potentiates mindfulness capacities in volunteers and induces rapid and sustained antidepressant effects in treatment-resistant patients. However, the mechanisms underlying these fast and maintained effects are poorly understood. Here, we investigated in an open-label uncontrolled study in 16 healthy volunteers ayahuasca-induced post-acute neurometabolic and connectivity modifications and their association with mindfulness measures. Methods: Using 1H-magnetic resonance spectroscopy and functional connectivity, we compared baseline and post-acute neurometabolites and seed-to-voxel connectivity in the posterior and anterior cingulate cortex after a single ayahuasca dose. Results: Magnetic resonance spectroscopy showed post-acute reductions in glutamate+glutamine, creatine, and N-acetylaspartate+N-acetylaspartylglutamate in the posterior cingulate cortex. Connectivity was increased between the posterior cingulate cortex and the anterior cingulate cortex, and between the anterior cingulate cortex and limbic structures in the right medial temporal lobe. Glutamate+glutamine reductions correlated with increases in the "nonjudging" subscale of the Five Facets Mindfulness Questionnaire. Increased anterior cingulate cortex-medial temporal lobe connectivity correlated with increased scores on the self-compassion questionnaire. Post-acute neural changes predicted sustained elevations in nonjudging 2 months later. Conclusions: These results support the involvement of glutamate neurotransmission in the effects of psychedelics in humans. They further suggest that neurometabolic changes in the posterior cingulate cortex, a key region within the default mode network, and increased connectivity between the anterior cingulate cortex and medial temporal lobe structures involved in emotion and memory potentially underlie the post-acute psychological effects of ayahuasca.
Overview
CoChat Summary
## TL;DR
In 16 healthy volunteers, a single ayahuasca dose was followed within 24 hours by posterior cingulate cortex neurometabolic decreases and increased functional connectivity between cingulate and limbic/default-mode-related regions. These post-acute neural changes were associated with higher mindfulness/self-compassion scores, with some correlations persisting at 2 months.
## Key findings
- In the posterior cingulate cortex (PCC), post-acute spectroscopy showed significant decreases in creatine (Cr) and N-acetylaspartate+N-acetylaspartylglutamate (NAA-NAAG), and a decrease in glutamate+glutamine (Glx) that was significant before correction but only marginal after FDR correction (P=.041; FDR P=.068).
- Functional connectivity increased post-acute between the PCC and anterior cingulate cortex (ACC), and between the ACC and limbic structures in the right medial temporal lobe; no areas showed decreased connectivity in the second-level analysis.
- Mindfulness-related scores increased post-acute: FFMQ nonjudging [t(15) = -2.92, P=.011, FDR=.021], nonreacting [t(15) = -2.61, P=.020, FDR=.031], EQ [t(15) = -3.58, P=.003, FDR=.011], Mindsens [t(15) = -3.63, P=.002, FDR=.011], and self-compassion [t(15) = -3.00, P=.009, FDR=.020].
- Exploratory correlations linked PCC Glx decreases with nonjudging increases (n=12; r=-0.589; P=.044), and ACC connectivity increases with nonjudging, nonreacting, and self-compassion scores; at 2 months, PCC Glx decreases and ACC connectivity increases still correlated with nonjudging change.
## Methods
- Open-label, uncontrolled pre/post study of 16 healthy volunteers (6 females) with prior ayahuasca experience; exclusion criteria included psychiatric disorders, substance dependence, significant illness, and pregnancy.
- Participants completed MRI-based assessments before ayahuasca and within 24 hours after intake, plus a 2-month questionnaire follow-up for 14/16 participants.
- Main analyses included repeated-measures ANOVA for MR spectroscopy metabolites, paired-samples t tests for mindfulness scores, and seed-to-voxel resting-state functional connectivity analyses with paired-samples t tests; correlations were exploratory and uncorrected for multiple comparisons.
## Limitations
- The paper states the study was small, open-label, and uncontrolled, with no placebo or time-effect control; it also recommends larger samples and double-blind, placebo-controlled designs.
- The paper states Glx quantification was available only in a smaller subset, and that the correlation analyses were exploratory and should be interpreted with caution.
- Evident from the text: all participants had prior ayahuasca experience and baseline mindfulness scores were already high, which may limit generalizability and create ceiling effects.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
0 Valid · 0 Not valid · 46 Not checked · 97 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Connectivity was increased between the posterior cingulate cortex and the anterior cingulate cortex”
§ Assessing the Psychedelic “After-Glow” in Ayahuasca Users: Post-Acute Neurometabolic and Functional Connectivity Changes Are Associated with Enhanced Mindfulness Capacities > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Post-acute neural changes predicted sustained elevations in nonjudging 2 months later.”
§ Assessing the Psychedelic “After-Glow” in Ayahuasca Users: Post-Acute Neurometabolic and Functional Connectivity Changes Are Associated with Enhanced Mindfulness Capacities > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and between the anterior cingulate cortex and limbic structures in the right medial temporal lobe.”
§ Assessing the Psychedelic “After-Glow” in Ayahuasca Users: Post-Acute Neurometabolic and Functional Connectivity Changes Are Associated with Enhanced Mindfulness Capacities > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Increased anterior cingulate cortex-medial temporal lobe connectivity correlated with increased scores on the self-compassion questionnaire.”
§ Assessing the Psychedelic “After-Glow” in Ayahuasca Users: Post-Acute Neurometabolic and Functional Connectivity Changes Are Associated with Enhanced Mindfulness Capacities > Abstract > Results
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Glutamate+glutamine reductions correlated with increases in the “nonjudging” subscale of the Five Facets Mindfulness Questionnaire.”
§ Assessing the Psychedelic “After-Glow” in Ayahuasca Users: Post-Acute Neurometabolic and Functional Connectivity Changes Are Associated with Enhanced Mindfulness Capacities > Abstract > Results
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
68 more claims
Create a free account to see all 143 claims and to verify the 77 references still open.
- The quote only partly states this claim. 2
- It may state two separate claims as one. 36
- Probably not a substantial claim. 50
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In the field of psychedelic neuroscience, reduced mPFC-PCC connectivity as well as DMN deactivation and disintegration have been demonstrated post-acutely after the administration of psilocybin, LSD and ayahuasca (45, 46, 57), while long-term ayahuasca users demonstrated thinning of the PCC (117).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [57]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, several studies have found positive associations between ayahuasca use and emotional acceptance processes, which appears to support the acute processing of previously avoided emotions and use of healthy emotion regulation strategies (Domínguez-Clavé et al., 2019; Franquesa et al., 2018; Sampedro et al., 2017; Soler et al., 2016, 2018).”
From Prospective examination of the therapeutic role of psychological flexibility and cognitive reappraisal in the ceremonial use of ayahuasca (2022) · cites this paper as Sampedro et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent studies have also demonstrated the capacity of various psychedelics to enhance trait mindfulness post-acutely, even in the absence of a theoretical or practical context of mindfulness training, evidencing a complementary relationship between mindfulness-training and psychedelics (40, 52, 56–59).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [57]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, enhanced acceptance towards present-moment thoughts and emotions has been observed post-acutely following the administration of ayahuasca and 5-MeO-DMT, which was maintained for up to 1 month (40, 52, 56–59).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [57]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Spontaneous enhancements in trait mindfulness have also been reported following the administration of various psychedelics, even outside of a mindfulness-enhancing context (40, 52, 56–59).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [57]
Experimental — accuracy not yet measured
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Statistics that don’t add up
Each reported p-value recomputed from its test statistic and degrees of freedom.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“F(1,12)=3.88, P=.075”
§ Assessing the Psychedelic “After-Glow” in Ayahuasca Users: Post-Acute Neurometabolic and Functional Connectivity Changes Are Associated with Enhanced Mindfulness Capacities > Results > MR Spectroscopy: Neurometabolite Assessment
Reported p = .075 · recomputed p = .072
Statistics recomputed
Every reported test result, recomputed from its test statistic and degrees of freedom. A result shows as not adding up only once an independent check has confirmed it.
- Doesn’t add upF(1, 12) = 3.88reported p = .075 · recomputed p = .072
“F(1,12)=3.88, p = .075”
- Not confirmedF(4, 48) = 0.55reported p = .606 · recomputed p = .700
“F(4,48)=0.55, p = .606”
- Not confirmedF(4, 44) = 0.54reported p = .632 · recomputed p = .707
“F(4,44)=0.54, p = .632”
- ConsistentF(4, 44) = 761reported p < .001 · recomputed p < .001
“F(4,44)= 761, p < .001”
- ConsistentF(4, 44) = 4.11reported p < .023 · recomputed p = .006
“F(4,44)=4.11, p < .023”
10 more recomputed tests
Create a free account to see every test the Stats check recomputed.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Citations
Cites
A default mode of brain function
Raichle, M. E., MacLeod, A. M., Snyder, A. Z., Powers, W. J., Gusnard, D. A., & Shulman, G. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.2.676 · Cited by 12,190
The human brain is intrinsically organized into dynamic, anticorrelated functional networks
Fox, M. D., Snyder, A. Z., Vincent, J. L., Corbetta, M., Van Essen, D. C., & Raichle, M. E. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504136102 · Cited by 8,553
Conn : A Functional Connectivity Toolbox for Correlated and Anticorrelated Brain Networks
Whitfield-Gabrieli, S., & Nieto-Castanon, A. (2012) · Brain Connectivity · doi:10.1089/brain.2012.0073 · Cited by 4,885
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Self-citationBrewer, J. A., Worhunsky, P. D., Gray, J. R., Tang, Y.-Y., Weber, J., & Kober, H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112029108 · Cited by 1,409 · cited 1×
“, 2014a), a population that also shows a pattern of decreased DMN-TPN anticorrelation (Brewer et al., 2011; Froeliger et al., 2012).”
BackgroundPilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206 · cited 1×
“Psychedelics are the object of renewed interest as potential therapeutic tools in psychiatry (Sessa, 2005; Vollenweider and Kometer, 2010; Grob et al., 2011).”
BackgroundNeural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172 · cited 1×
“MRS showed neurometabolic changes in the PCC, a region rich in 5-HT2A receptors (Carhart-Harris et al., 2012; Beliveau et al., 2016) and a target region of psychedelics (Palhano-Fontes et al., 2015; Carhart-Harris et al., 2016a; Valle et al., 2016).”
BackgroundSelf-citationPsilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
Griffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905
Research works printed but not linked: 1
- 2014, Assessing decentering: validation, psychometric properties and clinical usefulness of the Experiences Questionnaire in a Spanish sample, Behav Ther, 45, 863, 10.1016/j.beth.2014.05.004 · DOI · Paper page
Cited by
REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics
Carhart-Harris, R. L., & Friston, K. J. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017160 · Cited by 1,180
Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms
Carhart-Harris, R. L., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, J. N., Wall, M. B., Tanner, M., Kaelen, M., McGonigle, J., Murphy, K., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13282-7 · Cited by 587
The entropic brain - revisited
Carhart-Harris, R. L. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.03.010 · Cited by 522
Emotions and brain function are altered up to one month after a single high dose of psilocybin.
Barrett, F. S., Doss, M. K., Sepeda, N. D., Pekar, J. J., & Griffiths, R. R. (2020) · Scientific Reports · doi:10.1038/s41598-020-59282-y · Cited by 375
Doss, M. K., Považan, M., Rosenberg, M. D., Sepeda, N. D., Davis, A. K., Finan, P. H., Smith, G. S., Pekar, J. J., Barker, P. B., Griffiths, R. R., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01706-y · Cited by 356
Towards an understanding of psychedelic-induced neuroplasticity
Calder, A. E., & Hasler, G. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01389-z · Cited by 313
“It is possible that dendritic growth in PFC and ACC neurons is responsible for these effects [59].”
BackgroundEffective connectivity changes in LSD-induced altered states of consciousness in humans
Preller, K. H., Razi, A., Zeidman, P., Stämpfli, P., Friston, K. J., & Vollenweider, F. X. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1815129116 · Cited by 292
Reviewing the Potential of Psychedelics for the Treatment of PTSD
Krediet, E., Bostoen, T., Breeksema, J., van Schagen, A., Passie, T., & Vermetten, E. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa018 · Cited by 260
Long-term effects of psychedelic drugs: A systematic review
Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K., Davoli, C. C., & Davis, A. K. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.03.017 · Cited by 257
Default Mode Network Modulation by Psychedelics: A Systematic Review
Gattuso, J. J., Perkins, D., Ruffell, S., Lawrence, A. J., Hoyer, D., Jacobson, L. H., Timmermann, C., Castle, D., Rossell, S. L., Downey, L. A., et al. (2023) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac074 · Cited by 256
Smigielski, L., Scheidegger, M., Kometer, M., & Vollenweider, F. X. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.04.009 · Cited by 248
Uthaug, M. V., van Oorsouw, K., Kuypers, K. P. C., van Boxtel, M., Broers, N. J., Mason, N. L., Toennes, S. W., Riba, J., & Ramaekers, J. G. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4988-3 · Cited by 212
Self-citationGarcia-Romeu, A., & Richards, W. A. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1486289 · Cited by 189
Mertens, L. J., Wall, M. B., Roseman, L., Demetriou, L., Nutt, D. J., & Carhart-Harris, R. L. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119895520 · Cited by 208
Uthaug, M. V., Lancelotta, R., van Oorsouw, K., Kuypers, K. P. C., Mason, N., Rak, J., Šuláková, A., Jurok, R., Maryška, M., Kuchař, M., et al. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05236-w · Cited by 197
Self-citationMadsen, M. K., Fisher, P. M., Stenbæk, D. S., Kristiansen, S., Burmester, D., Lehel, S., Páleníček, T., Kuchař, M., Svarer, C., Ozenne, B., et al. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.02.001 · Cited by 183
Timmermann, C., Bauer, P. R., Gosseries, O., Vanhaudenhuyse, A., Vollenweider, F., Laureys, S., Singer, T., Antonova, E., & Lutz, A. (2023) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2022.11.006 · Cited by 150
Psychedelic harm reduction and integration: A transtheoretical model for clinical practice
Gorman, I., Nielson, E. M., Molinar, A., Cassidy, K., & Sabbagh, J. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.645246 · Cited by 147
“Afterglow Some individuals report a subjective positive experience of afterglow after a psychedelic experience, which may include heightened mood, psychological flexibility, openness, or mindfulness (Sampedro et al., 2017; Murphy-Beiner and Soar, 2020).”
BackgroundSpontaneous and deliberate creative cognition during and after psilocybin exposure
Mason, N. L., Kuypers, K. P. C., Reckweg, J. T., Müller, F., Tse, D. H. Y., Da Rios, B., Toennes, S. W., Stiers, P., Feilding, A., & Ramaekers, J. G. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01335-5 · Cited by 131
Self-citationAyahuasca’s ‘afterglow’: improved mindfulness and cognitive flexibility in ayahuasca drinkers
Murphy-Beiner, A., & Soar, K. (2020) · Psychopharmacology · doi:10.1007/s00213-019-05445-3 · Cited by 135
Subacute effects of the psychedelic ayahuasca on the salience and default mode networks
Pasquini, L., Palhano-Fontes, F., & Araujo, D. B. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120909409 · Cited by 119
Adverse effects of ayahuasca: Results from the Global Ayahuasca Survey
Bouso, J. C., Andión, Ó., Sarris, J. J., Scheidegger, M., Tófoli, L. F., Opaleye, E. S., Schubert, V., & Perkins, D. (2022) · PLOS Global Public Health · doi:10.1371/journal.pgph.0000438 · Cited by 118
dos Santos, R. G., & Hallak, J. E. C. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.12.001 · Cited by 111
Self-citationJiménez-Garrido, D. F., Gómez-Sousa, M., Ona, G., Dos Santos, R. G., Hallak, J. E. C., Alcázar-Córcoles, M. Á., & Bouso, J. C. (2020) · Scientific Reports · doi:10.1038/s41598-020-61169-x · Cited by 110
Self-citationMcCulloch, D. E.-W., Knudsen, G. M., Barrett, F. S., Doss, M. K., Carhart-Harris, R. L., Rosas, F. E., Deco, G., Kringelbach, M. L., Preller, K. H., Ramaekers, J. G., et al. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104689 · Cited by 120
Zeifman, R. J., Wagner, A. C., Watts, R., Kettner, H., Mertens, L. J., & Carhart-Harris, R. L. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00782 · Cited by 106
Soler, J., Elices, M., Dominguez-Clavé, E., Pascual, J. C., Feilding, A., Navarro-Gil, M., García-Campayo, J., & Riba, J. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00224 · Cited by 102
“(Soler et al., 2016; Sampedro et al., 2017).”
BackgroundMethodResultInfluentialSelf-citationNeural Mechanisms and Psychology of Psychedelic Ego Dissolution
Stoliker, D., Egan, G. F., Friston, K. J., & Razi, A. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000508 · Cited by 81
Does Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential?
Kočárová, R., Horáček, J., & Carhart-Harris, R. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.661233 · Cited by 96
Mason, N. L., Szabó, A., Kuypers, K. P. C., Mallaroni, P., de la Torre, R., Reckweg, J. T., Tse, D. H. Y., Hutten, N. R. P. W., Feilding, A., & Ramaekers, J. G. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.09.004 · Cited by 102
Self-citationThe Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Zaretsky, T. G., Jagodnik, K. M., Barsic, R., Antonio, J. H., Bonanno, P. A., MacLeod, C., Pierce, C., Carney, H., Morrison, M. T., Saylor, C. F., et al. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666231027111147 · Cited by 104
The impact of Ayahuasca on suicidality: results from a randomized controlled trial
Zeifman, R. J., Palhano-Fontes, F., Hallak, J., Arcoverde, E., Maia-Oliveira, J. P., & Araujo, D. B. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01325 · Cited by 87
“…is via increased mindfulness-related capacities (e.g., acceptance and decentering), which have been shown to increase after administration of ayahuasca (Thomas et al., 2013; Soler et al., 2016; Sampedro et al., 2017; Domínguez-Clavé et al., 2019; Soler et al., 2018; Uthaug et al., 2018).”
BackgroundResultSelf-citationDomínguez‐Clavé, E., Soler, J., Pascual, J. C., Elices, M., Franquesa, A., Valle, M., Álvarez, E., & Riba, J. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5085-3 · Cited by 94
Self-citationHeuschkel, K., & Kuypers, K. P. C. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00224 · Cited by 86
Tulver, K., Kaup, K., Laukkonen, R., & Aru, J. (2023) · Consciousness and Cognition · doi:10.1016/j.concog.2023.103494 · Cited by 97
Kiraga, M. K., Mason, N. L., Uthaug, M. V., van Oorsouw, K. I. M., Toennes, S. W., Ramaekers, J. G., & Kuypers, K. P. C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.721537 · Cited by 85
McCulloch, D. E.-W., Madsen, M. K., Stenbæk, D. S., Kristiansen, S., Ozenne, B., Jensen, P. S., Knudsen, G. M., & Fisher, P. M. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211026454 · Cited by 83
Psychedelics and Neural Plasticity: Therapeutic Implications
Grieco, S. F., Castrén, E., Knudsen, G. M., Kwan, A. C., Olson, D. E., Zuo, Y., Holmes, T. C., & Xu, X. (2022) · The Journal of Neuroscience · doi:10.1523/jneurosci.1121-22.2022 · Cited by 82
“…release in the human brain have been correlated to changes in brain volume (McKinnon et al., 2009; Santos et al., 2018), perturbations in task-related fMRI, and in resting state functional brain connectivity (Sampedro et al., 2017; Barrett et al., 2020; Madsen et al., 2021; McCulloch et al., 2022).”
Psychedelics as an emerging novel intervention in the treatment of substance use disorder: a review
Divito, A. J., & Leger, R. F. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-06009-x · Cited by 85
Combining Psychedelic and Mindfulness Interventions: Synergies to Inform Clinical Practice
Payne, J. E., Chambers, R., & Liknaitzky, P. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00034 · Cited by 78
Bejr‐kasem, H., Pagonabarraga, J., Martínez‐Horta, S., Sampedro, F., Marín‐Lahoz, J., Horta‐Barba, A., Aracil‐Bolaños, I., Pérez‐Pérez, J., Ángeles Botí, M., Campolongo, A., et al. (2019) · Movement Disorders · doi:10.1002/mds.27557 · Cited by 77
Self-citationTherapeutic potential of ayahuasca in grief: a prospective, observational study
González, D., Cantillo, J., Pérez, I., Farré, M., Feilding, A., Obiols, J. E., & Bouso, J. C. (2020) · Psychopharmacology · doi:10.1007/s00213-019-05446-2 · Cited by 75
Self-citationdos Santos, R. G., Bouso, J. C., Rocha, J. M., Rossi, G. N., & Hallak, J. E. (2021) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s300656 · Cited by 60
Self-citationJohnston, J. N., Kadriu, B., Allen, J., Gilbert, J. R., Henter, I. D., & Zarate, C. A. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109422 · Cited by 75
Positive psychology in the investigation of psychedelics and entactogens: a critical review
Jungaberle, H., Thal, S., Zeuch, A., Rougemont-Bücking, A., von Heyden, M., Aicher, H., & Scheidegger, M. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.06.034 · Cited by 70
Gandy, S., Forstmann, M., Carhart-Harris, R. L., Timmermann, C., Luke, D., & Watts, R. (2020) · Health Psychology Open · doi:10.1177/2055102920978123 · Cited by 63
Psychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
Giluk (2009) · doi:10.1017/s003329172000389x · Cited by 68
Sustained effects of single doses of classical psychedelics in humans
Knudsen, G. M. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01361-x · Cited by 79
Zeifman, R. J., & Wagner, A. C. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.11.001 · Cited by 67
Agin-Liebes, G., Nielson, E. M., Zingman, M., Kim, K., Haas, A., Owens, L. T., Rogers, U. A., & Bogenschutz, M. P. (2024) · Psychology of Addictive Behaviors · doi:10.1037/adb0000935 · Cited by 70
Mason, N. L., Theunissen, E. L., Hutten, N. R. P. W., Tse, D. H. Y., Toennes, S. W., Stiers, P. L. J., & Ramaekers, J. G. (2018) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.12.003 · Cited by 69
Sloshower, J., Zeifman, R. J., Guss, J., Krause, R., Safi-Aghdam, H., Pathania, S., Pittman, B., & D’Souza, D. C. (2024) · Scientific Reports · doi:10.1038/s41598-024-58318-x · Cited by 65
Mans, K., Kettner, H., Erritzøe, D., Haijen, E. C. H. M., Kaelen, M., & Carhart-Harris, R. L. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.647909 · Cited by 66
The pharmacological interaction of compounds in ayahuasca: a systematic review
Ruffell, S., Netzband, N., Bird, C., Young, A. H., & Juruena, M. F. (2020) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2020-0884 · Cited by 45
Leger, R. F., & Unterwald, E. M. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211044688 · Cited by 63
On the need for metaphysics in psychedelic therapy and research
Sjöstedt-Hughes, P. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1128589 · Cited by 66
Ona, G., & Bouso, J. C. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.09.035 · Cited by 58
An introduction to psychedelic neuroscience
Calvey, T., & Howells, F. M. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.09.013 · Cited by 63
Evens, R., Schmidt, M. E., Majić, T., & Schmidt, T. T. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231172254 · Cited by 56
Exploring DMT: Endogenous role and therapeutic potential
Schimmelpfennig, J., & Jankowiak-Siuda, K. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110314 · Cited by 58
Ayahuasca's therapeutic potential: What we know – and what not
Maia, L. O., Daldegan‐Bueno, D., Wießner, I., de Araújo, D. B., & Tófoli, L. F. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.10.008 · Cited by 61
Wießner, I., Falchi-Carvalho, M., Palhano-Fontes, F., Feilding, A., Ribeiro, S. T. G., & Tófoli, L. F. (2021) · Psychological Medicine · doi:10.1017/s0033291721002531 · Cited by 59
Self-citationAgin-Liebes, G., Zeifman, R., Luoma, J. B., Garland, E. L., Campbell, W. K., & Weiss, B. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221080165 · Cited by 54
“In addition, several studies have found positive associations between ayahuasca use and emotional acceptance processes, which appears to support the acute processing of previously avoided emotions and use of healthy emotion regulation strategies (Domínguez-Clavé et al., 2019; Franquesa et al., 2018; Sampedro et al., 2…”
BackgroundPsychedelic unselfing: self-transcendence and change of values in psychedelic experiences
Kähönen, J. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1104627 · Cited by 58
Yu, Z., Burback, L., Winkler, O., Xu, L., Dennett, L., Vermetten, E. H. G. J. M., Greenshaw, A. J., Li, X., Milne, M., Wang, F., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1386321 · Cited by 53
N,N‐dimethyltryptamine and Amazonian ayahuasca plant medicine
James, E., Keppler, J., Robertshaw, T. L., & Sessa, B. (2022) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2835 · Cited by 57
Ayahuasca’s Antidepressant Effects Covary with Behavioral Activation as Well as Mindfulness
Mian, M. N., Altman, B. R., & Earleywine, M. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1674428 · Cited by 46
Catalysts for change: the cellular neurobiology of psychedelics
Banks, M. I., Zahid, Z., Jones, N. T., Sultan, Z. W., & Wenthur, C. J. (2021) · Molecular Biology of the Cell · doi:10.1091/mbc.e20-05-0340 · Cited by 37
Egger, K., Aicher, H., Cumming, P. D., & Scheidegger, M. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05353-6 · Cited by 47
Koslowski, M., Johnson, M. W., Gründer, G., & Betzler, F. (2021) · Current Addiction Reports · doi:10.1007/s40429-021-00401-8 · Cited by 45
Orłowski, P., Ruban, A., Szczypiński, J., Hobot, J., Bielecki, M., & Bola, M. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221089034 · Cited by 41
“Taking into account that, in general, mindfulness practice is focused on the cultivation of perceptual awareness of one’s internal state, the observed effect can be linked to long-lasting increases in mindfulness-related capacities in psychedelic users (Sampedro et al., 2017; Uthaug et al., 2019).”
BackgroundEleftheriou, M. E., & Thomas, E. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.707057 · Cited by 39
“Individual studies also reported transient increases in self-compassion and present-moment awareness, as well as in the capacity to observe present-moment experience (40, 57, 58).”
BackgroundMethodResultInfluentialToward Mapping Neurobehavioral Heterogeneity of Psychedelic Neurobiology in Humans
Moujaes, F., Preller, K. H., Ji, J. L., Murray, J. D., Berkovitch, L., Vollenweider, F. X., & Anticevic, A. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.10.021 · Cited by 40
Barsuglia, J. P., Polanco, M., Palmer, R., Malcolm, B. J., Kelmendi, B., & Calvey, T. (2018) · Progress in Brain Research · doi:10.1016/bs.pbr.2018.08.002 · Cited by 38
Psychedelic-Assisted Therapy for Substance Use Disorders and Potential Mechanisms of Action
Rieser, N. M., Herdener, M., & Preller, K. H. (2021) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2021_284 · Cited by 37
Nootropic effects of LSD: Behavioral, molecular and computational evidence
Ornelas, I. M., da Silva, F. A. C., Wießner, I., Marcos, E., de Araújo, D. B., Goto‐Silva, L., Nascimento, J. M., Silva, S. R. B., Costa, M., Falchi-Carvalho, M., et al. (2022) · Experimental Neurology · doi:10.1016/j.expneurol.2022.114148 · Cited by 38
Self-citationBenefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression
Ramaekers, J. G., Reckweg, J. T., & Mason, N. L. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230890 · Cited by 37
Dourron, H. M., Strauss, C. K., & Hendricks, P. S. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000514 · Cited by 41
Dimethyltryptamine: Endogenous Role and Therapeutic Potential
Rodrigues, A. V., Almeida, F., & Vieira‐Coelho, M. A. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1602291 · Cited by 38
Ayahuasca and tobacco smoking cessation: results from an online survey in Brazil
Daldegan‐Bueno, D., Maia, L. O., Massarentti, C. M., & Tófoli, L. F. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06063-2 · Cited by 39
How does ayahuasca work from a psychiatric perspective? Pros and cons of the entheogenic therapy
Orsolini, L., Chiappini, S., Papanti, D., Latini, R., Volpe, U., Fornaro, M., Tomasetti, C., Vellante, F., & Berardis, D. D. (2020) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2728 · Cited by 37
Ayahuasca may help to improve self‐compassion and self‐criticism capacities
Domínguez‐Clavé, E., Soler, J., Elices, M., Franquesa, A., Álvarez, E., & Pascual, J. C. (2021) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2807 · Cited by 38
Self-citationPsychedelics as Novel Therapeutics in Alzheimer’s Disease: Rationale and Potential Mechanisms
Garcia‐Romeu, A., Darcy, S., Jackson, H., White, T., & Rosenberg, P. B. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_267 · Cited by 36
Perkins, D., Ruffell, S., Day, K., Rubiano, D. P., & Sarris, J. J. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.879221 · Cited by 54
Psychedelics and mindfulness: A systematic review and meta-analysis
Radakovic, C., Radaković, R., Peryer, G., & Geere, J. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00218 · Cited by 34
Politi, M., Tresca, G., Menghini, L., & Ferrante, C. (2021) · Planta Medica · doi:10.1055/a-1675-3840 · Cited by 35
The potential of psychedelics for the treatment of Alzheimer's disease and related dementias
Winkelman, M., Szabó, A., & Frecska, E. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.07.003 · Cited by 35
Frymann, T., Whitney, S., Yaden, D. B., & Lipson, J. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.863247 · Cited by 30
Psychological effects of psychedelics in adolescents
Izmi, N., Carhart-Harris, R. L., & Kettner, H. (2024) · Frontiers in Child and Adolescent Psychiatry · doi:10.3389/frcha.2024.1364617 · Cited by 31
Calder, A. E., Hase, A., & Hasler, G. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02830-z · Cited by 25
SANTOS, R. G. D., Rocha, J. M., Rossi, G. N., Osório, F. D. L., Oña, G., Bouso, J. C., Silveira, G. D. O., Yonamine, M., Marchioni, C., Crevelin, E. J., et al. (2022) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2834 · Cited by 23
Self-citationScheidegger, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-55688-4_3 · Cited by 24
Ayahuasca and the traveller: A scoping review of risks and possible benefits
Houle, S. K. D., Evans, D., Carter, C. A., & Schlagenhauf, P. (2021) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2021.102206 · Cited by 20
Barrett, F. S., Zhou, Y., Carbonaro, T. M., Roberts, J., Smith, G. S., Griffiths, R. R., & Wong, D. F. (2022) · Frontiers in Neuroergonomics · doi:10.3389/fnrgo.2021.784576 · Cited by 21
Psychedelics and environmental virtues
Kirkham, N., & Letheby, C. (2022) · Philosophical Psychology · doi:10.1080/09515089.2022.2057290 · Cited by 22
Meling, D., Egger, K., Aicher, H., Redondo, J. J., Mueller, J., Dornbierer, J., Temperli, E., Vasella, E. A., Caflisch, L., Pfeiffer, D., et al. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241282637 · Cited by 24
Daldegan‐Bueno, D., Révész, D., Morais, P. R., Barbosa, P. C. R., & Maia, L. O. (2022) · Substance Use & Misuse · doi:10.1080/10826084.2022.2063896 · Cited by 21
Psychedelic Experience: Revealing the Mind
Lyon, A. (2023) · doi:10.1093/oso/9780198843757.001.0001 · Cited by 29
van Oorsouw, K. I. M., Uthaug, M. V., Mason, N. L., Broers, N. J., & Ramaekers, J. G. (2021) · Journal of Psychedelic Studies · doi:10.1556/2054.2021.00174 · Cited by 20
Metadata
- Authors
- Sampedro, F., de la Fuente Revenga, M., Valle, M., Roberto, N., Domínguez-Clavé, E., Elices, M., Luna, L. E., Crippa, J. A. S., Hallak, J. E. C., de Araujo, D. B., Friedlander, P., Barker, S. A., Álvarez, E., Soler, J., Pascual, J. C., Feilding, A., & Riba, J.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- ORCID
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-06-13
- Volume
- 20
- Issue
- 9
- Pages
- 698-711
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC5581489
- OpenAlex
- W2616273018
- Semantic Scholar
- b0995e4954d6fef2bf65bfd7d47bd21f6087bd23
- Cited by
- 200
- References
- 74
- Citations by year
- 2026: 16 · 2025: 19 · 2024: 26 · 2023: 35 · 2022: 27 · 2021: 32 · 2020: 18 · 2019: 14 · 2018: 11 · 2017: 1
- FWCI
- 14.92
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (publishedVersion, other-oa)
- Americanae (AECID Library) (submittedVersion, other-oa)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by-nc)
- Funders
- Beckley Foundation
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Social Sciences › Psychology › Social Psychology › Paranormal Experiences and Beliefs
- Keywords
- ayahuasca, psychedelics, mindfulness, non-judgment, self-compassion, posterior cingulate cortex, anterior cingulate cortex, medial temporal lobe, default mode network, glutamate, neurometabolites, functional connectivity, N,N-dimethyltryptamine, harmala alkaloids, antidepressant effects
- MeSH terms
- Adult, Aspartic Acid, Brain Mapping, Cerebral Cortex, Female, Follow-Up Studies, Hallucinogens, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Magnetic Resonance Spectroscopy, Surveys and Questionnaires, Time Factors, Glutamic Acid, Imaging, Three-Dimensional, Banisteriopsis, Healthy Volunteers, Mindfulness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.